All GLG News Analyses Filed Under: Oncology

More is NOT NECESSARILY better in metastatic colorectal carcinoma.

February 5, 2009

Analysis by: GLG Expert Contributor

Analysis of:Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | nejm.highwire.org

"...Many targeted agents are available or under development for use in a wide range of tumors. The inhibition of a single signal-transduction pathway is unlikely to provide optimal results, and therefore a combination of agents appears to be a valid strategy. Our results, however, argue against the combined use of anti-VEGF and anti-EGFR monoclonal antibodies with chemotherapy in cases of metastatic colorectal cancer."

Tarceva + Avastin Beats Avastin Alone in Adenocarcinoma of the Lung...

February 4, 2009

Analysis by: GLG Expert Contributor

Analysis of:OSI, Genentech Say Cancer Drug’s Benefits Ends Trial (Update2) | www.bloomberg.com

Tarceva, when added to Avastin, as maintenance therapy after standard chemo in adenocarcinomas of the lung, prolonged disease progression. The ATLAS trial will make this the standard of care post initial therapy in >50% of lung cancers (about 50,000+ patients/year.)

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

HPV vaccination: do we have to think twice?

January 26, 2009

Analysis of:Merck’s Gardasil Should Not Be Mandatory: Report | www.pharmalot.com

HPV vaccine in Italy is recommended and free for 12-year old girls, but recently several petitions have been presented in order to think back to this vaccination due to the fact that safety and effectiveness are not clear enough.

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

Maintenance therapy in NSCLC: the jury is still out?

January 26, 2009

Analysis of:Tarceva successful as maintenance therapy | www.fiercebiotech.com

Tarceva (as well as Alimta) has shown interesting results in the maintenance setting. Nevertheless will an increase of only a few weeks in PFS justify its use (and the cost) or will we need to wait for survival data?

Gastric cancer trial: Phase II but may well be "the real deal"

January 20, 2009

Analysis by: GLG Expert Contributor

Analysis of:Afinitor(R) Phase II trial results positive in patients with advanced gastric cancer after failure of one or more prior treatments | www.pipelinereview.com

This m-TOR inhibitor appears to show efficacy in this phase II trial. Before anointing it a success let's see what phase III trials show.

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

Positive reults in Japanese with gastric cancer can be extended to the Western population?

January 20, 2009

Analysis of:Afinitor(R) Phase II trial results positive in patients with advanced gastric cancer after failure of one or more prior treatments | www.pipelinereview.com

Afinitor (everolimus) is a promising drug in several solid tumors. Results of the phase II trial in gastric cancer are interesting, but they have been obtained in Japanese population.

Donald FlemingDivision Head of Hematology and OncologyDAVIS HEALTH SYSTEM INC

Algeta completes comprehensive phase II clinical program with Alpharadin for treating bone metastases in patients with advanced prostate cancer

January 15, 2009

Analysis of:Algeta completes comprehensive phase II clinical program with Alpharadin for treating bone metastases in patients with advanced prostate cancer | www.pipelinereview.com

prostate cancer patients have  bone mets as a major problem Radioisotopic therapy has been designed to address the issue

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

Strategy of treatment in mCRC

January 15, 2009

Analysis of:Merck Serono: Study Published In JCO Shows Erbitux Enhances Efficacy In MCRC Patients With KRAS Wild-Type Tumors In 1st-Line Setting | www.medicalnewstoday.com

Patients with k-ras wild type can obtain good response from cetuximab. The introduction of cetuximab in the first line setting plays an important role in the global strategy of mCRC. In Europe the coming approval of panitumumab may also change the sequence of therapy in the above mentioned setting of disease.

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE

Caution in drawing conclusions

January 15, 2009

Analysis of:Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months | www.drugs.com

Unfortunately the results of the FLEX trial presented at ASCO meeting in 2008 do not seem amazing for a medical oncologist who treat NSCLC patients. Therefore it could be very useful to select patients who can receive real benefits from erbitux in combination with chemotherapy. Skin toxicity may represent an easy clinical parameter which can help the oncologists in this situation, nevertheless several flaws need to be considered.

Erbitux enhances efficacy in MCRC patients

January 8, 2009

Analysis by: GLG Expert Contributor

Analysis of:Merck Serono: Study Published In JCO Shows Erbitux Enhances Efficacy In MCRC Patients With KRAS Wild-Type Tumors In 1st-Line Setting | www.medicalnewstoday.com

 To treat MCRC patients  with KRAS wild type tumors is  a challening  task. To overcome it   the combination therapy of Erbitux and  standard oxaliplatin-based chemotherapy (FOLFOX-4) is highly  positive news for patients and care givers.

Previous Page : 12345678910Next51 to 60 of 900